A detailed history of Stifel Financial Corp transactions in Compugen LTD stock. As of the latest transaction made, Stifel Financial Corp holds 52,065 shares of CGEN stock, worth $77,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,065
Previous 51,659 0.79%
Holding current value
$77,576
Previous $86,000 9.3%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.56 - $2.1 $633 - $852
406 Added 0.79%
52,065 $94,000
Q2 2024

Aug 13, 2024

SELL
$1.68 - $2.52 $1,853 - $2,779
-1,103 Reduced 2.09%
51,659 $86,000
Q1 2024

May 13, 2024

BUY
$1.75 - $2.95 $3,942 - $6,646
2,253 Added 4.46%
52,762 $136,000
Q4 2023

Feb 12, 2024

BUY
$0.53 - $2.0 $710 - $2,680
1,340 Added 2.73%
50,509 $100,000
Q3 2023

Nov 13, 2023

BUY
$0.88 - $1.31 $33 - $49
38 Added 0.08%
49,169 $45,000
Q2 2023

Aug 14, 2023

BUY
$0.57 - $1.38 $554 - $1,341
972 Added 2.02%
49,131 $56,000
Q1 2023

May 12, 2023

BUY
$0.68 - $1.11 $1,039 - $1,697
1,529 Added 3.28%
48,159 $33,000
Q4 2022

Feb 13, 2023

SELL
$0.58 - $1.2 $26 - $55
-46 Reduced 0.1%
46,630 $33,000
Q3 2022

Nov 14, 2022

SELL
$0.66 - $2.32 $105 - $371
-160 Reduced 0.34%
46,676 $31,000
Q2 2022

Aug 15, 2022

BUY
$1.57 - $3.33 $131 - $279
84 Added 0.18%
46,836 $87,000
Q1 2022

May 13, 2022

BUY
$2.76 - $4.64 $31,072 - $52,237
11,258 Added 31.72%
46,752 $151,000
Q4 2021

Feb 14, 2022

BUY
$4.09 - $7.16 $145,170 - $254,137
35,494 New
35,494 $153,000
Q4 2020

Feb 12, 2021

SELL
$12.07 - $17.95 $137,006 - $203,750
-11,351 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$14.16 - $19.45 $160,730 - $220,776
11,351 New
11,351 $184,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $129M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.